Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

The European Respiratory Journal
Gérald SimonneauIrene M Lang

Abstract

In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH). 43 adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomised three to one to receive either selexipag or placebo. Dosage was up-titrated in 200-μg increments from 200 μg twice daily on day 1 to the maximum tolerated dose by day 35 (maximum allowed dose of 800 μg twice daily). Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analysed in the per protocol set first and then in the all-treated set to assess robustness of results. A statistically significant 30.3% reduction in geometric mean pulmonary vascular resistance was observed after 17 weeks' treatment with selexipag compared with placebo (95% confidence limits -44.7- -12.2; p=0.0045, Wilcoxon rank sum test). This was supported by a similar result from the all-treated set. Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect...Continue Reading

Citations

Oct 15, 2013·Current Hypertension Reports·Yan WuMarc Humbert
Aug 3, 2013·Current Opinion in Pulmonary Medicine·Sonja D Bartolome
Oct 12, 2014·Current Hypertension Reports·Aaron M WolfsonMardi Gomberg-Maitland
Jan 10, 2014·American Journal of Respiratory and Critical Care Medicine·Soni Savai PullamsettiWerner Seeger
Oct 12, 2013·Paediatric Drugs·Erika E Vorhies, David Dunbar Ivy
Jul 3, 2013·American Journal of Respiratory and Critical Care Medicine·Martin R WilkinsMark T Gladwin
Oct 19, 2013·Pharmacology & Therapeutics·David MontaniMarc Humbert
Jun 26, 2013·High Altitude Medicine & Biology·Dustin Fraidenburg, Jason Yuan
Jan 8, 2014·Expert Opinion on Pharmacotherapy·Nika Skoro-Sajer, Irene Marthe Lang
Nov 17, 2015·Expert Review of Respiratory Medicine·Kamal Sharma
Aug 21, 2015·Expert Opinion on Pharmacotherapy·Swanny PerrinOlivier Sitbon
Oct 21, 2015·Expert Opinion on Investigational Drugs·Mayank SardanaHarrison W Farber
Feb 6, 2016·Drugs·Lesley J Scott
Nov 26, 2013·Rheumatic Diseases Clinics of North America·Saman Ahmed, Harold I Palevsky
Nov 26, 2013·Clinics in Chest Medicine·Meredith E PughIvan M Robbins
Jan 23, 2016·Heart Failure Reviews·Tomas PulidoJennifer Escobar
Mar 10, 2016·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Manreet K KanwarJean-Luc Vachiéry
Sep 10, 2013·Pulmonary Circulation·Simon MalenfantSébastien Bonnet
Jan 11, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Caroline O'ConnellOlivier Sitbon
Dec 24, 2015·Pulmonary Circulation·Joshua P Fessel, James D West
Feb 13, 2016·Expert Review of Clinical Pharmacology·Pierangelo Chinello, Nicola Petrosillo
Dec 25, 2015·The New England Journal of Medicine·Olivier SitbonP G Williams
Sep 20, 2015·American Heart Journal·Kishan S ParikhZainab Samad
May 9, 2015·Journal of the American College of Cardiology·Vallerie V McLaughlinMarc Humbert
Jul 6, 2016·The Canadian Journal of Cardiology·Benjamin D FoxMordechai R Kramer
Apr 15, 2016·Acta Clinica Belgica·Els H VandecasteeleV Smith
Mar 5, 2016·The Lancet. Respiratory Medicine·Annie Christine LajoieSteeve Provencher
Jul 17, 2016·Best Practice & Research. Clinical Rheumatology·Ragnar GunnarssonØyvind Molberg
Feb 11, 2015·Expert Opinion on Pharmacotherapy·Frédéric LadorMaurice Beghetti
Jun 13, 2015·Current Hypertension Reports·Alison M MacKenzie, Andrew J Peacock
Jul 30, 2014·Medicina clínica·Antonio RomanEnric Domingo
May 9, 2015·The Journal for Nurse Practitioners : JNP·Joanna Wapner, Lea Ann Matura
Jan 19, 2016·Global Cardiology Science & Practice·A M ChakrabartiS J Wort
Apr 4, 2015·The Canadian Journal of Cardiology·Steeve Provencher, John T Granton
Sep 1, 2014·Pulmonary Pharmacology & Therapeutics·Ya-Guo ZhengChang-Ming Xiong
Dec 7, 2014·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Stephan Rosenkranz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved